[Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
| Autor: | Garcia-Estevez DA; Complexo Hospitalario de Ourense, Ourense, Espana., Pardo-Parrado M; Complexo Hospitalario de Ourense, Ourense, Espana., Silvarrey-Rodriguez S; Complexo Hospitalario de Ourense, Ourense, Espana. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Revista de neurologia [Rev Neurol] 2017 Aug 16; Vol. 65 (4), pp. 153-156. |
| Abstrakt: | Introduction: The pathophysiology of pain in migraine is related to the activation of the trigeminovascular system by releasing vasoactive neuropeptides, the most important of which is calcitonin gene-related peptide (CGRP), which causes a neurogenic inflammation in the leptomeningeal vessels. Aim: To study whether CGRP is increased in frequent episodic migraine and whether preventive treatment with topiramate or zonisamide modifies its levels. Subjects and Methods: We studied 28 patients with episodic migraine with or without aura, in accordance with the International Headache Society criteria, with a frequency of 4-14 days/month. Plasma levels of CGRP were determined in all the patients during an interictal period (> 72 hours without pain). Patients were divided at random into two treatment groups, one with 50 mg/day of topiramate and the other with 50 mg/day of zonisamide, for three months. At the end of the active period the CGRP level was analysed again. The control group consisted of nine healthy subjects. Results: CGRP was significantly higher in the episodic migraine group than in the control group (50.61 ± 22.5 pg/mL versus 34.96 ± 17.03 pg/mL; p = 0.037). After treatment with neuromodulators no significant differences were found in the level of CGRP (46.11 ± 24.2 pg/mL basal versus 47.5 ± 24.88 pg/mL post-treatment). Neither were any differences found on analysing the topiramate and zonisamide groups individually. Conclusions: The plasma level of CGRP is increased in episodic migraine, and its levels are not modified by treatment with low doses of topiramate or zonisamide. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|